Analyzing Baxter International (NYSE:BAX) and NWT Uranium (OTCMKTS:CPTRF)

NWT Uranium (OTCMKTS:CPTRF) and Baxter International (NYSE:BAX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

90.2% of Baxter International shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for NWT Uranium and Baxter International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NWT Uranium	0	0	0	0	0.00
Baxter International	2	10	2	0	2.00

Baxter International has a consensus target price of $22.00, suggesting a potential upside of 15.97%. Given Baxter International’s stronger consensus rating and higher possible upside, analysts plainly believe Baxter International is more favorable than NWT Uranium.

Valuation and Earnings

This table compares NWT Uranium and Baxter International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NWT Uranium	$27.25 million	N/A	$6.69 million	$4.08	0.04
Baxter International	$10.64 billion	0.92	-$649.00 million	($0.66)	-28.74

NWT Uranium has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than NWT Uranium, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NWT Uranium and Baxter International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NWT Uranium	N/A	-103.88%	-95.46%
Baxter International	-3.09%	17.38%	5.57%

Summary

Baxter International beats NWT Uranium on 8 of the 12 factors compared between the two stocks.

About NWT Uranium

Captor Capital Corp. engages in the manufacture and retail sale of cannabis products in the United States. It operates two dispensaries under the CHAI Cannabis Co. brand in Santa Cruz and Monterey, California, as well as operates an e-commerce site under the CHAI-brand. The company was formerly known as NWT Uranium Corp. and changed its name to Captor Capital Corp. in June 2017. Captor Capital Corp. was incorporated in 2003 and is based in Toronto, Canada.

About Baxter International

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.